Diabetes drug takes on brain cancer: could sitagliptin help fight glioblastoma?
NCT ID NCT07003542
First seen May 09, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This phase 2 trial tests whether sitagliptin, a diabetes drug, can improve the immune system's ability to fight glioblastoma, an aggressive brain tumor. The study will enroll 48 adults with progressive grade 4 gliomas who are scheduled for tumor removal surgery. Some participants will receive sitagliptin before surgery, while others will not, to compare immune cell activity in the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sitagliptin
What this could lead to
If it works, this could point toward a new way to help the immune system fight glioblastoma, potentially slowing tumor growth.
What could go wrong
This is an early phase 2 trial with only 48 people, so results may not apply broadly. Sitagliptin is not yet proven for brain tumors, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.